In the past five years, the performance of nearly half of the biopharmaceutical companies is expected to be good, and many CXO companies have performed well.

According to Securities Times, as of January 22nd when the journalist was writing the article, more than 50 biopharmaceutical companies have disclosed their performance forecasts for 2025 according to the Shenwan industry classification, with 27 of them expecting better performance, making up nearly half of the total. It is worth noting that several CXO companies have shown impressive performance. Among them, the industry leader Yifan Kangde is expected to achieve an operating income of approximately 45.456 billion yuan in 2025, a year-on-year increase of approximately 15.84%; achieving a net profit attributable to the parent company of approximately 19.151 billion yuan, a year-on-year increase of approximately 102.65%. Industry insiders believe that with the gradual recovery of global investment and financing, continued support for the innovative drug industry in China, and the gradual recovery of new drug research and development, the CXO industry is trending positively. In 2026, with the deepening of structural reforms in the industry, and the continuous optimization of policies and financing environment, the trend of improving the quality and upgrading of the Chinese pharmaceutical industry will be clear, ushering the industry into a new stage of high-quality development.